SBRVX
Price
$18.02
Change
+$0.26 (+1.46%)
Updated
Jun 2 closing price
Net Assets
425.85M
VRTIX
Price
$450.82
Change
+$4.04 (+0.90%)
Updated
Jun 2 closing price
Net Assets
16.58B
Interact to see
Advertisement

SBRVX vs VRTIX

Header iconSBRVX vs VRTIX Comparison
Open Charts SBRVX vs VRTIXBanner chart's image
SBRVX vs VRTIX Comparison Chart in %
View a ticker or compare two or three
VS
SBRVX vs. VRTIX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SBRVX is a Buy and VRTIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VRTIX has more cash in the bank: 16.6B vs. SBRVX (426M). VRTIX pays higher dividends than SBRVX: VRTIX (1.07) vs SBRVX (0.29). SBRVX was incepted earlier than VRTIX: SBRVX (6 years) vs VRTIX (15 years). SBRVX (1.29) is less costly to investors than VRTIX (0.05). SBRVX is a more actively managed with annual turnover of: 39.00 vs. VRTIX (14.00). SBRVX has a lower initial minimum investment than VRTIX: SBRVX (2500) vs VRTIX (5000000). VRTIX annual gain was more profitable for investors over the last year : 40.83 vs. SBRVX (30.59). VRTIX return over 5 years is better than : 29.82 vs. SBRVX (15.80).
SBRVXVRTIXSBRVX / VRTIX
Total Expense Ratio1.140.052,280%
Annual Report Gross Expense Ratio1.290.052,580%
Fund Existence6 years15 years-
Gain YTD18.87617.423108%
Front LoadN/AN/A-
Min. Initial Investment250050000000%
Min. Initial Investment IRAN/AN/A-
Net Assets426M16.6B3%
Annual Yield % from dividends0.291.0727%
Returns for 1 year30.5940.8375%
Returns for 3 years42.1860.6570%
Returns for 5 years15.8029.8253%
Returns for 10 yearsN/A160.34-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RVSB5.600.08
+1.45%
Riverview Bancorp
ULS97.77-2.17
-2.17%
UL Solutions
UTZ7.07-0.16
-2.21%
Utz Brands
SNTG2.11-0.07
-3.21%
Sentage Holdings
RCUS24.47-1.20
-4.67%
Arcus Biosciences